SEQUENCE LISTING

	<110> SOLVAY PHARMACEUTICALS B.V.	
5	<120> Novel Human G-Protein coupled Receptor	
	<130> SPW 99.07	
10	<140> <141>	
	<160> 9	
15	<170> PatentIn Ver. 2.1	
00	<210> 1 <211> 1176 <212> DNA <213> Homo sapiens	
20	<220> <221> CDS * <222> (149)(1138)	
25	<400> 1 ttaatctctt caagcctctg atttcctctc ctgtaaaaca ggggcggtaa ttacc	acata 60
	acaggetggt catgaaaatc agtgaacatg cagcaggtgc tcaagtcttg ttttt	gtttc 120
30	caggggcacc agtggaggtt ttctgagc atg gat cca acc acc ccg gcc to Met Asp Pro Thr Thr Pro Ala To 1	
35	gga aca gaa agt aca aca gtg aat gga aat gac caa gcc ctt ctt c Gly Thr Glu Ser Thr Thr Val Asn Gly Asn Asp Gln Ala Leu Leu 1 10 15 20	
40	ctt tgt ggc aag gag acc ctg atc ccg gtc ttc ctg atc ctt ttc c Leu Cys Gly Lys Glu Thr Leu Ile Pro Val Phe Leu Ile Leu Phe 25 30 35	
45	gcc ctg gtc ggg ctg gta gga aac ggg ttt gtg ctc tgg ctc ctg g Ala Leu Val Gly Leu Val Gly Asn Gly Phe Val Leu Trp Leu Leu 6 45 50 55	
	ttc cgc atg cgc agg aac gcc ttc tct gtc tac gtc ctc agc ctg g Phe Arg Met Arg Arg Asn Ala Phe Ser Val Tyr Val Leu Ser Leu 60 65 70	
50	ggg gcc gac ttc ctc ttc ctc tgc ttc cag att ata aat tgc ctg Gly Ala Asp Phe Leu Phe Leu Cys Phe Gln Ile Ile Asn Cys Leu 75 80 85	

					ttc Phe												460
5					atg Met												508
10					acc Thr 125												556
15	Tyr	Arg	Cys	Arg 140	cgc Arg	Pro	Arg	His	Leu 145	Ser	Ala	Val	Val	Cys 150	Val	Leu	604
20	Leu	Trp	Ala 155	Leu	tcc Ser	Leu	Leu	Leu 160	Ser	Ile	Leu	Glu	Gly 165	Lys	Phe	Cys	652
	Gly	Phe 170	Leu	Pne	agt Ser	Asp	Gly 175	Asp	Ser	Gly	Trp	Cys 180	Gln	Thr	Phe	Asp	700
25	Phe 185	Ile	Thr	Ala	gcg Ala	Trp 190	Leu	Ile	Phe	Leu	Phe 195	Met	Val	Leu	Cys	Gly 200	748
30	Ser	Ser	Leu	Ala	ctg Leu 205	Leu	Val	Arg	Ile	Leu 210	Cys	Gly	Ser	Arg	Gly 215	Leu	796
35	Pro	Leu	Thr	Arg 220	ctg Leu	Tyr	Leu	Thr	Ile 225	Leu	Leu	Thr	Val	Leu 230	Val	Phe	844
40	Leu	Leu	Cys 235	Gly	ctg Leu	Pro	Phe	Gly 240	Ile	Gln	Trp	Phe	Leu 245	Ile	Leu	Trp	892
45	Ile	Trp 250	Lys	Asp	tct Ser	Asp	Val 255	Leu	Phe	Cys	His	Ile 260	His	Pro	Val	Ser	940
45	Val 265	Val	Leu	Ser	tct Ser	Leu 270	Asn	Ser	Ser	Ala	Asn 275	. Pro	Ile	Ile	Tyr	Phe 280	988
50	Phe	val	Gly	Ser	Phe 285	Arg	Lys	Gln	Trp	290	Leu	Gln	Gln	Pro	Ile 295	Leu	1036
55					caç Glr					Asp					Asp		1084

	78
V	

5	agt Ser	gaa Glu	gga Gly 315	tgc Cys	ttc Phe	cgt Arg	cag Gln	ggc Gly 320	Thr	ccg Pro	gag Glu	atg Met	tcg Ser 325	aga Arg	agc Ser	agt Ser	1132
	ctg Leu		taga	gato	gga c	agco	etcta	ac ti	ccat	caga	a tat	atgt	-g				1176
10																	
15	<210> 2 <211> 330 <212> PRT <213> Homo sapiens																
)> 2 Asp	Pro	Thr	Thr 5	Pro	Ala	Trp	Gly	Thr	Glu	Ser	Thr	Thr	Val 15	Asn	
25	Gly	Asn	Asp	Gln 20	Ala	Leu	Leu	Leu	Leu 25	Cys	Gly	Lys	Glu	Thr 30	Leu	Ile	
30			35					40		Leu			45				
	Ser	50					55			Ala		60					
35	65 Phe	Gln	Ile	Ile	Asn 85	70 Cys	Leu	.Val	Tyr	Leu 90	75 Ser	Asn	Phe	Phe	Cys 95	80 Ser	
40	Ile	Ser	Ile	Asn 100		Pro	Ser	Phe	Phe 105	Thr	Thr	Val	Met	Thr		Ala	
45	Tyr	Leu	Ala 115		Leu	Ser	Met	Leu 120	Ser	Thr	Val	Ser	Thr 125	Glu	Arg	Cys	
	` -	130					135			Arg		140					
50	145					150			•	Trp	155					160	
55		***	200	<u> </u>	165	пyэ	FIIC	cys	GIÀ	170	neu	rne	ser	Asp	175	ASD	

26

Ser Gly Trp Cys Gln Thr Phe Asp Phe Ile Thr Ala Ala Trp Leu Ile 180 185 Phe Leu Phe Met Val Leu Cys Gly Ser Ser Leu Ala Leu Leu Val Arg 5 200 Ile Leu Cys Gly Ser Arg Gly Leu Pro Leu Thr Arg Leu Tyr Leu Thr 215 10 Ile Leu Leu Thr Val Leu Val Phe Leu Leu Cys Gly Leu Pro Phe Gly 230 235 Ile Gln Trp Phe Leu Ile Leu Trp Ile Trp Lys Asp Ser Asp Val Leu 250 15 Phe Cys His Ile His Pro Val Ser Val Val Leu Ser Ser Leu Asn Ser 260 Ser Ala Asn Pro Ile Ile Tyr Phe Phe Val Gly Ser Phe Arg Lys Gln 20 Trp Arg Leu GIn Gln Pro Ile Leu Lys Leu Ala Leu Gln Arg Ala Leu 295 25 Gln Asp Ile Ala Glu Val Asp His Ser Glu Gly Cys Phe Arg Gln Gly 305 310 Thr Pro Glu Met Ser Arg Ser Ser Leu Val 325 30 <210> 3 <211> 26 35 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Degenerated 40 primers <220> <221> variation <222> (21) 45 <223> A,C,G or T <220> <221> variation <222> (24) 50 <223> A,C,G or T <400> 3 ctgcactacc acgtgctcws nytngc 55

```
<210> 4
     <211> 28
     <212> DNA
     <213> Artificial Sequence
 5
     <220>
     <223> Description of Artificial Sequence: Degenerated
           primers
10
     <220>
     <221> variation
     <222> (21)
     <223> A,C,G or T
15
     <220>
     <221> variation
     <222> (27)
     <223> C or Inosine
20
     <400> 4
     gggtggcaga tggccarrya nckytcnb
                                                                          28
25
     <210> 5
     <211> 31
30
     <212> DNA
     <213> Artificial Sequence
     <223> Description of Artificial Sequence: Degenerated
35
           primers
     <220>
     <221> variation
     <222> (25)
40
     <223> A,C,G or T
     <400> 5
     gtggcagatg gccaggcagc grtcnrcrct d
                                                                          31
45
     <210> 6
     \<211> 28
      <212> DNA
      <213> Artificial Sequence
50
      <220>
      <223> Description of Artificial Sequence: Primer
      <400> 6
55
      ggggccgact tcctcttcct ctgcttcc
                                                                          28
```



	<210> 7	
	<211> 28	
5	<212> DNA	
	<213> Artificial Sequence	
	<220>	
10	<223> Description of Artificial Sequence: Primer	
.0	<400> 7	
	gcaaggtagg cacaggtcat cacagtgg	28
15	<210> 8	
13	<210> 8 <211> 31	
	<211> 31 - (212> DNA)	
	<213> Artificial Sequence	
20	<220>	
	<223> Description of Artificial Sequence: Primer	
	<400> 8	
	ataagcttct ccctggccct taataaatga c	31
25		
	<210> 9	
	<211> 29	
20	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: Primer	
35	<400> 9	
	aggaattcag acagacaggg gcaaagttg	29